Online Message
After receiving your message, our professional team will contact you shortly.
Capabilities in Tumor Efficacy Evaluation
-
Oncology overviewOncology Service HighlightCustomized and multi-dimensional protocol based on targets
SPF animal facility
License for the use of experimental animals: SYXK (Shanghai) 2022-0028Barrier system: rat, mouseOpen system: rabbitAddress：West side of floor 1, Zone B, No.735 ZipingRoad, PudongNewAreaOncology ServicesSerial number Production Service content Input Output Delivery period 1 In vivo pharmacology Syngeneic model - Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)2 In vivo pharmacology CDX model - Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)3 In vivo
pharmacologyPBMC model - Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)4 In vivo
pharmacologyTransgenic mice
model- Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)5 Pharmacological
testFACS assays - Tumor samples
- Peripheral blood
FACS assay
reportOne week 6 Pharmacological
testCytokine assays - Tumor samples
- Peripheral blood
Cytokine assays
reportOne week 7 Pharmacological
testHematology test - Tumor samples
- Peripheral blood
Hematology test
reportOne week 8 Pharmacological
testPathological
test- Tumor samples
- Animal organ samples
- Scanned image of sample
- Pathological test report
2-3 weeks
4-5 weeks
(cus-tomized) -
Preclinical Oncology ModelsSyngeneic
model30 + models validated for antibody and small moleculeLeukemia, breast, lung, colon, melanoma, kidney, bladder and liver etc.CDX
modelNude, NOD-SCID, and NSG model availableLeukemia, breast, lung, colon, skin, pancreatic, stomach, ovary, prostate and liver etc.Humanized
modelhPBMC modelmPBMC modelhCD34 modelKI + hCD34 modelHumanized
tumor cellHumanized cellCell lines: (50 + available)Reliable cell supplyTransgenic mice:
Biocytogen
Genpharma
CyagenIVIS
platformSystemic models available in houseMetastasis and orthotopic modelsMultiple Luc-cell lines availableTissue distribution studies provide reliable results -
Syngeneic modelsList Of Syngeneic Models
Cell line Tissue Disease Mouse strain Available models MC38 colon colorectal
carcinomaC57BL/6 subcutaneous CT-26 large intestine colorectal carcinoma BALB/C subcutaneous 4T1 mammary gland breast cancer BALB/C subcutaneous
orthotopicEL4 T lymphocyte lymphoma C57BL/6 subcutaneous E0771 mammary gland breast carcinoma C57BL/6 subcutaneous LLC lung lung carcinoma C57BL/6 subcutaneous B16F10 skin melanoma C57BL/6 subcutaneous
metastasis(i.v.)ROR1-B16F10 skin melanoma C57BL/6 subcutaneous Pan02 pancreas adenocarcinoma C57BL/6 subcutaneous Growth Curves of Syngeneic Mouse Model
-
CDX ModelsList Of CDX Models
Cell line Tissue Disease Mouse strain Available models HT-29 colon colorectal
adenocarcinomanude subcutaneous NCI-N87 stomach gastric carcinoma nude subcutaneous NCI-H1975 lung NSCLC nude subcutaneous JIMT-1 breast breast carcinoma nude subcutaneous HCT116 colon colorectal carcinoma nude,NSG subcutaneous Colo205 colon colorectal adenocarcinoma nude subcutaneous NCI-H1581 lung NSCLC nude subcutaneous Hep-2 larynx carcinoma nude subcutaneous Detroit 562 pharynx pharyngeal carcinoma NKG subcutaneous SW48 colon colorectal adenocarcinoma NOD SCID subcutaneous PC-3 Lung lung adenocarcinoma nude subcutaneous 22RV1 Prostate carcinoma nude subcutaneous SK-OV-3 ovary adenocarcinoma nude subcutaneous U-87 MG brain glioblastoma NOD SCID subcutaneous
orthotopicA375 skin malignant melanoma NSG subcutaneous Growth Curves of CDX Model
Efficacy Study in NCI-N87 Xenograft Model
ConclusionNo body weight loss was observed during observation. Data are presented as Mean±SEM
Superior tumor suppression was observed in the HER2-positive NCI-N87 xenograft model treated with Trastuzumab
-
PBMC-humanized modelsPBMC ModelsPBMC-transfer induced humanized mouse model
-
PBMC sources
Human Genetic Resources
Chinese and foreigner
PBMC Characterization
-
Mice
NSG/NCG/NOG
B-NDG
NSG- SGM3
NSG-IL15
-
Reconstruction
s.c mix & i.v
Day -14/-10/-2/2
-
Tumor
TME analysis
Biomarker analysis
Cytokine analysis
-
-
IVIS platformIVIS for Orthotopic and Metastatic Models
IVIS case studiesVariety of Luc-cell lines available
IVIS collaboration studies on-going
-
IHC Staining and drug-resistant cellsIHC Staining for targets in mouse and Human tumor samplesImmunohistochemistry Staining
HE
Ki67
CD31
HER2
EGFR
TROP2Biomarker, tumor antigen and receptor staining and bi-staining
Cytokines, chemokines, transcription factor and antibody detections
Customized Biomarkers for cell typing in lymphocytes, NK cells, macrophages, and neutrophils
Drug-resistant Cell LinesCategories Targets SOC Tumor cell Chemotherapy Chemotherapy Docetaxel SNU-16、22RV1、A549、NCI-H1299、KYSE150、KYSE520、AGS、MDA-MB-231 Cisplatin A2780、A549、NCI-H1299、Cal-27、KYSE30、KYSE150、KYSE520、AGS、HT-29、MDA-MB-231 Doxorubicin OVCAR8、NALM6 Oxaliplatin HGC-27、AGS Target therapy EGFR Gifitinib PC-9、HCC827 Osimertinib NCI-H1975、HCC-827、PC-9 C-met Savolitinib
Crizotinib
SavolitinibHs746T、NCI-H1993 ROS1/ALK Lorlatinib NCI-H3122 PARP Niraparib SK-OV-3 ADC HER2 Enhertu
(DS8201)HCC-827、KYSE150、NCI-N87